Actively Recruiting
Study of Riluzole to Reduce Paroxysmal Atrial Fibrillation Episodes A Phase 2, Randomized, Double-Blind Trial Using Holter Monitoring
Led by University of Utah · Updated on 2023-11-24
78
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Atrial fibrillation AF is a common heart rhythm disorder that causes episodes of irregular heartbeat and can lead to serious health problems. Researchers are evaluating riluzole, a drug currently used for amyotrophic lateral sclerosis ALS, to see if it can reduce episodes of AF safely and effectively. The study is a phase 2, prospective, randomized, placebo-controlled trial comparing riluzole to placebo in patients with paroxysmal AF. Participants will be randomly assigned to receive either riluzole 50mg twice daily or a matching placebo for one month. Before starting the medication, patients will undergo cardioversion to restore normal heart rhythm. Heart rhythm will be continuously monitored using a chest-worn, nonadhesive Holter monitor throughout the 30-day treatment period to track AF episodes. After the initial month, patients without AF recurrence and tolerating the drug may continue riluzole in an open-label extension for an additional 90 days with follow-up phone calls. Patients will have blood tests before and after the treatment period to monitor safety, including checks for heart rhythm disturbances and blood cell counts. Weekly phone calls will assess symptoms and side effects. The main outcomes measured are the number of AF episodes and the time to the first AF episode during the 30-day treatment. Safety and tolerability of riluzole compared to placebo will also be evaluated. After the study, patients will continue care with their own doctors.
CONDITIONS
Brief Title
RiLuzole to Reduce Atrial FIb Study Using Holter Monitoring
Research Team
M
Mark A Munger, Pharm.D.
J
John Kirk
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here